Fluvoxamine eases fatigue associated with long COVID The widely-available antidepressant fluvoxamine is one of the first medications shown to meaningfully reduce fatigue in people living with long COVID, a global, randomised, placebocontrolled clinical trial, published in the Annals of Internal Medicine has shown
Longitudinal analyses of circulating tumor DNA for the detection of egfr mutation-positive advanced NSCLC progression during treatment: data from FLAURA and AURA3
Despite these potential benefits, its crucial to remember that research is still emerging, and the FDA has not approved BPC-157 for any medical use
En conclusion, les bienfaits du glutathion vont bien au-del de la sant de la peau, ce qui en fait un antioxydant essentiel au bien-tre gnral
Elevated mycotoxin levels can contribute to a range of health issues, including respiratory problems, neurological symptoms, and immune dysfunction